CHD Bioscience Enters into Research and Development Agreement with Colorado State University to Explore New Ways of Treating Infectious Disease

CHD Bioscience, Inc. announced the completion of a Master Research and Development Agreement with Colorado State University.

Mike Handley, chief executive officer, said, “This research agreement will help facilitate further collaborative work with CSU’s Mycobacterium Research Lab group as well as other Infectious Disease Research faculty who can utilize CHD technology to find new ways of treating some of the most prolific infectious diseases in industrialized and developing countries.”

According to Ed Neas, Ph.D., chief technology officer for CHD, “We look forward to collaborating with some of the top researchers in the field of infectious disease.”

The Master Research and Development Agreement between CHD Bioscience and Colorado State outlines the working relationship between CHD and CSU researchers. It contains pre-negotiated terms for licensing of potential future intellectual property that may be derived from this working relationship. CHD intends to initiate work with faculty in the areas of chemistry enhancement, mycobacterium treatment, prion treatment, cutaneous and pulmonary infections.

“This type of collaborative research relationship is a critical link in moving innovation from the laboratory into real products and services that can directly address the growing needs in the infectious disease field,” said Bill Farland, CSU’s vice president for Research.

About CHD

CHD Bioscience is a multi-product development-stage healthcare company that has created a technology platform for the prevention and treatment of infectious disease. Specifically, CHD Bioscience is focusing on the prevention and treatment of hospital acquired infections (HAI) that result in more than 100,000 deaths a year in the U.S. and cost the U.S. healthcare system more than $30 billion a year. HAIs are the result of many sources, primarily healthcare facility surfaces, medical devices, acute/chronic wounds and surgical wound care. Currently, CHD Bioscience products in development address all these HAI sources. CHD Bioscience is located in the Research Innovation Center on the CSU campus in Fort Collins, Colo. For additional information, visit

Any questions related to this announcement should be directed to Mike Handley or Bob Kali at or at (970) 492-4364.